Pharmacy Inside Jobs: ADHD assessment and management In this episode of Pharmacy Inside Jobs, Gurmat Khangura talks about how he has brought his skills and experience as a pharmacist to his role assessing and managing young people with neurodevelopmental conditions.…
Help us understand current pharmacy practice in migraine management by sharing your experience Please complete our short survey, which should take no more than seven minutes to complete.…
Coroner writes to ICB following death of patient who took too many of their prescribed drugs The ‘Prevention of future deaths’ report, published on 16 April 2025, was issued following the death of patient who was waiting for mental health support.…
NICE recommends cladribine for treating active relapsing forms of multiple sclerosis Cladribine (Mavenclad; Merck) is recommended for treating active relapsing-remitting multiple sclerosis in adults when high-efficacy disease-modifying therapies would be offered.…
Stimulant and non-stimulant agents for ADHD This medication guide details the different types of treatments for attention deficit hyperactivity disorder, for both adults and children.…
Patients in emergency departments should be supported to self-administer time-critical medicines, says royal college Advice produced with the UK Clinical Pharmacy Association urges that emergency departments should hold self-administered time-critical medicines to the same monitoring and governance oversight standards as non self-administered medicines.…
Alzheimer’s treatments donanemab and lecanemab still not recommended under latest NICE draft guidance NICE says that the cost of implementing donanemab and lecanemab across the NHS is “significantly higher” than considered acceptable for taxpayers’ money and NHS resources.…
First non-cannabis treatment for rare form of epilepsy made available on NHS Fenfluramine is a non-cannabis treatment for patients with Lennox-Gastaut syndrome who do not respond to existing treatments or clobazam owing to its side effects.…
Two-clinician review for men taking valproate not required, says MHRA The requirement that two specialists must review any patient aged under 55 years taking valproate will now only apply to patients who are starting the drug.…
The novel schizophrenia drug showing renewed potential for better outcomes A novel acetylcholine receptor drug has become the first new medicine to treat schizophrenia in decades. But even after gaining approval in the United States, experts are still conflicted on its benefits over current antipsychotic medicines.…
